Puretech Health Plc (PRTC) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Bristol Myers Squibb has completed the acquisition of Karuna Therapeutics, a PureTech Health founded entity, for $14 billion, focusing on the schizophrenia treatment KarXT. PureTech is set to receive approximately $293 million from its equity in Karuna, alongside potential milestones and royalties from KarXT’s future successes. The deal marks a significant advancement for PureTech and promises to reshape treatment options for schizophrenia patients.
For further insights into PRTC stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue